PROM1 and colorectal cancer: Although JIB-04 treatment did not markedly reduce the overall viability of the colorectal cancer cells (Fig. 1A), it significantly decreased a representative CSC marker, CD133, in a dose-dependent manner (Fig. 2A,B).